ライフサイエンスコーパス: checkpoint

1 o override the p53-dependent G2/M cell-cycle checkpoint.

2 t are therefore eliminated by the DNA-damage checkpoint.

3 1 plays an important role in the replication checkpoint.

4 by tumor cell death, which enforces the CD73-checkpoint.

5 ion, and inactivated a third, the DNA damage checkpoint.

6 ment and their progression through the pre-B checkpoint.

7 ry receptors is an important quality control checkpoint.

8 upts host innate immune signaling at various checkpoints.

9 atumoral heterogeneity of interacting immune checkpoints.

10 inst post-translationally modified proteins (checkpoint 1).

11 synovitis from acute to chronic destructive (checkpoint 3).

12 Furthermore, we found that the immune checkpoint 4-1BB had a high selectivity for human tumor

13 trate that targeted inhibition of cell cycle checkpoint activation following ionizing radiation drive

14 ells show slower DNA replication, DNA damage checkpoint activation, and an increased apoptotic rate.

15 ecombination-dependent replication (RDR) and checkpoint activation.

16 tion sites perturbs Aurora B recruitment and checkpoint activation.

17 s mitotic entry, likely via transient G(2)/M checkpoint activation.

18 tion through regulating the spindle assembly checkpoint activity, and cyclin B1 and securin degradati

19 and identify dietary, epithelial, and immune checkpoints along this axis to be potentially exploitabl

20 tients with metastatic melanoma using immune checkpoint and tyrosine kinase inhibitors (TKI), the maj

21 tomic analyses reveal enrichment of the G2/M checkpoint and up-regulation of Polo-like kinase 1 (PLK1

22 arily based on blockade of one or two immune checkpoints and has a lower predictability of response b

23 hibitor AZD1775 (WEE1i) overrides cell cycle checkpoints and is being studied in HNSCC regimens.

24 onsistent basic data suggest that these same checkpoints are critical negative regulators of atherosc

25 nt mechanisms contributing to these distinct checkpoints are not well defined.

26 the lagging strand, resulting in DNA damage-checkpoint arrest and cell death.

27 NA-PK as essential regulators of replication checkpoint arrest in response to AZD1775 and defined PTE

28 Myeloid checkpoints as well as the tumour and tissue contexture

29 e human inhibitory FcgammaRIIb is a critical checkpoint balancing protective and autoreactive immune

30 Here we applied these checkpoint based fitness measures to the matched checkpo

31 been associated with poor outcome to immune checkpoint blockade (1), this has not been comprehensive

32 Treatment with immune checkpoint blockade (ICB) has revolutionized cancer ther

33 e the outstanding clinical results of immune checkpoint blockade (ICB) in melanoma and other cancers,

34 Immune checkpoint blockade (ICB) is efficacious in many diverse

35 Immune checkpoint blockade (ICB) therapy has improved patient s

36 has been implicated in resistance to immune checkpoint blockade (ICB) therapy(1-3).

37 s involving metabolic inhibitors with immune checkpoint blockade (ICB), chemotherapy, radiation, and/

38 d resistance to immunotherapy such as immune checkpoint blockade (ICB).

39 mor immunity and improved efficacy of immune checkpoint blockade (ICB).

40 states with clinical outcomes during immune checkpoint blockade and chimeric antigen receptor (CAR)

41 Oncolytic vectors engineered to express checkpoint blockade antibodies and cytokines could provi

42 vaccine, Lmdd-MPFG, and the anti-PD-1 immune checkpoint blockade antibody.

43 h RCC and combinatorial approaches involving checkpoint blockade are now standard of care in patients

44 Patients who received checkpoint blockade before DC vaccination had higher bas

45 e IIIB-IV NSCLC who were treated with immune checkpoint blockade between June 2011 and December 2017

46 py, TGFbeta signaling inhibition, and immune checkpoint blockade effectively restores antitumor immun

47 Pharmacological immune checkpoint blockade has revolutionized oncological thera

48 ive breast cancer (TNBC) does not respond to checkpoint blockade immunotherapy as a result of immunos

49 The advent of checkpoint blockade immunotherapy over the past few year

50 le negative breast cancer and facilitate the checkpoint blockade immunotherapy.

51 multaneously heightens sensitivity to immune checkpoint blockade in a murine model of melanoma.

52 not support a response-adaptive strategy for checkpoint blockade in advanced RCC.

53 tric surgery-induced weight loss, and immune checkpoint blockade in cancer.

54 vo therapy-induced senescent cells to immune checkpoint blockade in vivo.

55 The majority of irAEs from checkpoint blockade involve either barrier tissues (e.g.

56 cation of reliable biomarkers of response to checkpoint blockade is crucial to facilitate improvement

57 Immune checkpoint blockade is one of the most promising strateg

58 so showed improved outcomes under PD1 immune checkpoint blockade relative to APOE2 mice, and patients

59 Clinical studies with IL17 and checkpoint blockade represent a novel combinatorial ther

60 Immune checkpoint blockade represents a promising approach in o

61 rogramming nanoparticles in combination with checkpoint blockade significantly reduced tumor growth o

62 Immune checkpoint blockade therapies have extended patient surv

63 Immune checkpoint blockade therapies have shown clinical promis

64 Cs could benefit from PD1 and/or PDL1 immune checkpoint blockade therapy.

65 uggest that targeting BMI1 may enable immune checkpoint blockade to inhibit metastatic tumor growth a

66 n improved outcomes of sarcomatoid tumors to checkpoint blockade versus antiangiogenics alone, and de

67 ntrinsically sensitive to SHP2 inhibition or checkpoint blockade were particularly susceptible.

68 l demonstrate synergistic efficacy of immune checkpoint blockade with the MDSC-diminishing drugs cabo

69 reactivate antileukemia immunity (vaccines, checkpoint blockade).

70 h conditions, while responsiveness to immune checkpoint blockade, a form of cancer immunotherapy, is

71 onment and acts cooperatively with anti-PD-1 checkpoint blockade, offering a combination immunotherap

72 tal adenocarcinoma (PDAC) responds poorly to checkpoint blockade, such as anti-CTLA-4 and anti-PD-1.

73 eed, targeting glutamine metabolism rendered checkpoint blockade-resistant tumors susceptible to immu

74 is resistant to both chemotherapy and immune checkpoint blockade.

75 ssential for the antitumor effects of immune checkpoint blockade.

76 otherapy with programmed cell death-1 (PD-1) checkpoint blockade.

77 immune rejection in combination with immune checkpoint blockade.

78 an be exploited to improve response rates to checkpoint blockade.

79 rns coordinated selective response to immune checkpoint blockade.

80 SHP2 modulated T-cell infiltrates similar to checkpoint blockade.

81 chromatin recognition and response to immune checkpoint blockade.

82 BACKGROUNDThe recent failure of checkpoint-blockade therapies for glioblastoma multiform

83 key indicators of a good response to immune checkpoint blockers in independent patient cohorts.

84 e now also increasingly combined with immune-checkpoint blockers.

85 sing clinical benefit of targeted and immune checkpoint blocking therapeutics, current strategies hav

86 ngs, comprises genes involved in the spindle checkpoint (BUB1, MAD1, BIM1, and KAR3), and they all sh

87 s indicate that when m-Tyr has passed the QC checkpoint by the PheRS, this toxicity of m-Tyr may resu

88 LMP2A affected apoptosis and cell-cycle checkpoints by dysregulating the expression of apoptosis

89 s, we propose that the CIP participates in a checkpoint, capable of triggering a CAR constriction del

90 mitotic regulator cyclin B1 and the spindle checkpoint component Mad1 was independently described by

91 The DNA damage checkpoint (DDC) is often robustly activated during the

92 domain of these human enzymes may cause the checkpoint defect and contribute to the cancer predispos

93 are required to mediate the DNA replication checkpoint (DRC), the stable pausing of forks at protein

94 Thus, modulation of CTLA-4 or OX40 immune checkpoints during vaccination can promote germinal cent

95 ulatory T-cells; and transcription of immune checkpoint (e.g., PD-1, LAG3) genes.

96 AAA-ATPase PCH-2/TRIP13, which remodels the checkpoint effector Mad2 from an active conformation to

97 Here we show that the DNA-damage checkpoint eliminates oocytes via the pro-apoptotic BCL-

98 rations in DNA repair enzymes and cell-cycle checkpoints, elucidation of factors enabling the genomic

99 T cells, elevated IFN signaling, and immune checkpoint expression, as well as increased antigen pres

100 luding elevated TGFbeta signaling and immune checkpoint expression, as well as increased antigen pres

101 show that TL closing and opening provides a checkpoint for NTP complementarity, NTP ribo/deoxyribo i

102 GTPBP5 provides an ultimate quality control checkpoint function during mtLSU assembly that minimizes

103 Therefore, the replication checkpoint function of Rqh1 is highly conserved, and mut

104 High immune checkpoint gene expression networks correlated with infe

105 gate the relationship between CYT and immune checkpoint gene score (ICGscore), as well as their corre

106 ased expression of cell cycle and DNA damage checkpoint genes (false discovery rate <0.25; normalized

107 We demonstrate that spindle checkpoint genes act upstream of Isc1, and their deletio

108 omic repeats (CRISPR)-Cas9 editing of immune checkpoint genes could improve the efficacy of T cell th

109 rize the role of immune cells and inhibitory checkpoints, genome-wide frequencies of copy number alte

110 cell death 1 pathway as an important immune checkpoint has the potential to obviate the need for chr

111 Polo-like kinase 1-interacting checkpoint helicase (PICH) is a DNA translocase essentia

112 s) is dictated by immunoglobulin heavy chain checkpoint (IgHCC), where the IgHC encoded by a producti

113 tumor microenvironment that could potentiate checkpoint immunotherapy for glioblastoma.

114 isms of resistance to alphaPD-1/PD-L1 immune-checkpoint immunotherapy is key to developing new treatm

115 Checkpoint immunotherapy unleashes T cell control of tum

116 es the response of patients with melanoma to checkpoint immunotherapy(1,2).

117 ed, eukaryotic specific and dynamic fidelity checkpoint implemented by eIF5B in concert with componen

118 and the sensor kinase of the DNA replication checkpoint in Schizosaccharomyces pombe Under replicatio

119 r data instead identify maturation through a checkpoint in the pathway as the cargo-sensitive step.

120 intestinal barrier integrity as an important checkpoint in translating autoimmunity to inflammation.

121 restricted cell type expression and roles as checkpoints in immune cell responses in human diseases s

122 l-intrinsic IRF5 regulates multiple distinct checkpoints in T cell activation and differentiation and

123 We discovered these gating checkpoints in the middle and cytosolic extended TM doma

124 in T cells, thereby boosting spontaneous and checkpoint-induced tumour immunity.

125 romote cancer cell proliferation by reducing checkpoint--induced cell-cycle arrest during interphase.

126 3.7 months, p < 0.001), but not after immune checkpoint inhibition (CPI).

127 While immune-checkpoint inhibition (ICI) proved clinical efficacy in

128 Ten of 11 patients were treated with immune checkpoint inhibition at some point in the treatment cou

129 y in mouse models of breast cancer increases checkpoint inhibition by activating antigen-presenting c

130 ation, intravitreous melphalan, and systemic checkpoint inhibition can be used in the treatment of op

131 Most patients received checkpoint inhibition for the treatment of systemic dise

132 Targeting immune suppression using checkpoint inhibition has resulted in clinical responses

133 riety of cancer subtypes, the role of immune checkpoint inhibition in the treatment of prostate cance

134 ge may be a causative factor and that immune checkpoint inhibition may be beneficial.

135 Immune checkpoint inhibition reactivates immunity against tumor

136 PD-L1 negative tumors respond to PD-1/PD-L1 checkpoint inhibition remains unclear.

137 New immunotherapies based on checkpoint inhibition targeting the immune receptor TIGI

138 nts, particularly in recently evolved immune checkpoint inhibition therapy.

139 grammed cell death protein 1 or PD-L1 immune checkpoint inhibition, further validation of SUV against

140 diated T cell suppression and, together with checkpoint inhibition, improved the efficacy of cancer i

141 e has expanded to include immunotherapy with checkpoint inhibition, targeted therapies, and antibody-

142 The recent advent of immune checkpoint inhibitor (CPI) antibodies has revolutionized

143 Immune checkpoint inhibitor (ICI) therapy is often accompanied

144 d as a monotherapy and in combination with a checkpoint inhibitor and/or chemotherapy in locally adva

145 more prominent when combined with the immune checkpoint inhibitor anti-PD-1, strengthening the ration

146 We tested our approach using the immune checkpoint inhibitor anti-PD-L1-gamma1 as an effector ge

147 e that the active delivery of anti-CTLA-4 (a checkpoint inhibitor drug) results in greatly enhanced i

148 These results support the premise that checkpoint inhibitor drugs hold considerable therapeutic

149 d patients with metastatic RCC with no prior checkpoint inhibitor exposure.

150 following chemotherapy as a promising immune checkpoint inhibitor for cancer treatment.

151 Immunotherapy with atezolizumab, a checkpoint inhibitor targeting the programmed cell death

152 bladder cancer is found in the use of immune checkpoint inhibitor therapeutics.

153 ision node can be applied to optimize immune checkpoint inhibitor therapy for cancer treatment.

154 yet provide a strong rationale for trials of checkpoint inhibitor therapy for sepsis.

155 le success has sparked interest in expanding checkpoint inhibitor therapy in infectious diseases.

156 n pump inhibitor use, and combination immune checkpoint inhibitor therapy were each independently ass

157 the range of adverse effects associated with checkpoint inhibitor therapy.

158 able of driving effective response to immune checkpoint inhibitor therapy.

159 micronuclei formation utilizing a cell cycle checkpoint inhibitor to drive cell cycle progression fol

160 eening for latent tuberculosis before immune checkpoint inhibitor treatment in cancer is not routine,

161 is virus (LCMV) infection, it was shown that checkpoint inhibitor treatment increased T cell prolifer

162 antigen-specific CD8(+) TCR repertoire under checkpoint inhibitor treatment.

163 were then combined with alphaPD-1, an immune checkpoint inhibitor, and ultrasound-mediated hypertherm

164 , particularly in combination with an immune checkpoint inhibitor, reduces tumor growth and is a pote

165 d death-ligand 1 antibody (aPDL1), an immune checkpoint inhibitor, released from the MN patch further

166 lure to achieve kidney recovery after immune checkpoint inhibitor-associated AKI was independently as

167 associated with an increased risk of immune checkpoint inhibitor-associated AKI.

168 ection, but improved after discontinuing the checkpoint inhibitor.

169 resistant to other therapies, such as immune checkpoint inhibitors (ICI), and individuals succumb to

170 Immune checkpoint inhibitors (ICIs) are standard therapy in met

171 Although immune checkpoint inhibitors (ICIs) have achieved unprecedented

172 Immune checkpoint inhibitors (ICIs) have transformed cancer tre

173 Immune checkpoint inhibitors (ICIs) have transformed the treatm

174 Immune checkpoint inhibitors (ICIs) treat an expanding range of

175 Expanding use of immune-checkpoint inhibitors (ICIs) underscores the importance

176 Immune checkpoint inhibitors (ICIs), monoclonal antibodies that

177 The advent of immune checkpoint inhibitors (ICIs), which have proven to be ef

178 e of interest was prior initiation of immune checkpoint inhibitors (ICIs).

179 mmune events in patients treated with immune checkpoint inhibitors (ICIs).

180 fferent recombinant viruses: NDVs expressing checkpoint inhibitors (rNDV-anti-PD1 and rNDV-anti-PDL1)

181 unotherapeutic interventions, such as use of checkpoint inhibitors and adoptive T cell transfer, have

182 or vaccines, cell-based therapies and immune-checkpoint inhibitors and discuss the potential for pati

183 Immune checkpoint inhibitors are a potential option for patient

184 Although checkpoint inhibitors are already used as therapy agains

185 store T cell repertoire diversity.IMPORTANCE Checkpoint inhibitors are effective immunotherapeutics t

186 Checkpoint inhibitors are effective in restoring exhaust

187 Checkpoint inhibitors are now frequently used for oncolo

188 cipients with metastatic cancer who received checkpoint inhibitors at a single center between April 2

189 ndings indicate frequent discontinuations of checkpoint inhibitors at one year.

190 The remarkable success of immune checkpoint inhibitors demonstrates the potential of tumo

191 ls and regulatory actions of approved immune checkpoint inhibitors for small cell lung cancer, discus

192 oncogenic BRAF->MEK->ERK pathway and immune checkpoint inhibitors for the treatment of metastatic me

193 on of molecularly targeted agents and immune-checkpoint inhibitors has led to improved survival outco

194 Consistent with this role, PD-1 checkpoint inhibitors have been associated with immune-r

195 Checkpoint inhibitors have been proposed for sepsis foll

196 been proposed to predict response to immune checkpoint inhibitors in melanoma and small-cell lung ca

197 ing the therapeutic efficiency of anti-PD-L1 checkpoint inhibitors in vivo.

198 Evidence shows that the response to checkpoint inhibitors may be associated with type and de

199 ter survival and improved response to immune-checkpoint inhibitors of melanoma patients.

200 ernative in cancers that are not amenable to checkpoint inhibitors or other immunotherapies.

201 cancer for which immune modulation by immune checkpoint inhibitors shows remarkable response rates.

202 Immune checkpoint inhibitors targeting PD-1 have shown clinical

203 th recent success in immunotherapy using the checkpoint inhibitors, additional investigations are ess

204 velopment of in situ cancer vaccines, immune checkpoint inhibitors, adoptive cell transfer, and bispe

205 tational burden is a major hurdle for immune checkpoint inhibitors, an immature or impaired immune sy

206 T-cell effector response targeting including checkpoint inhibitors, and gene editing.

207 inoma who benefit from treatment with immune checkpoint inhibitors, either alone or in combination re

208 cutaneous melanoma to chemotherapy or immune checkpoint inhibitors, encouraging results have been rep

209 es enhance anti-tumor immune responses using checkpoint inhibitors, such as PD-1 or PD-L1 inhibitors.

210 as shown by regulatory approvals for immune checkpoint inhibitors.

211 esting potential clinical response to immune checkpoint inhibitors.

212 ARID2 knockout sensitizes melanoma to immune checkpoint inhibitors.

213 (TME) and enhancing response rates to immune checkpoint inhibitors.

214 ients demonstrate durable response to immune checkpoint inhibitors.

215 anced cancer patient treated with PD-1/PD-L1 checkpoint inhibitors.

216 apy, particularly in combination with immune checkpoint inhibitors.

217 nhibition may augment the activity of immune checkpoint inhibitors.

218 and is associated with resistance to immune checkpoint inhibitors.

219 ing toolbox of targeted therapies and immune-checkpoint inhibitors.

220 proteins correlated with response to immune checkpoint inhibitors.

221 hes with antibody-drug conjugates and immune checkpoint inhibitors.

222 and could improve patient stratification for checkpoint inhibitory drugs.

223 e issue of patient stratification for immune checkpoint intervention, we quantitatively imaged PD-1/P

224 ronment, reflected in the efficacy of immune checkpoint interventions, further prompts to incorporate

225 Molecular insight into this checkpoint is lacking.

226 -telangiectasia mutated (ATM) and cell cycle checkpoint kinase 2 (CHK2), a DNA damage response (DDR)

227 hree different mechanisms of cell killing by checkpoint kinase I inhibitors (CHK1i).

228 e Trp53 tumor suppressor or Chek2 DNA damage checkpoint kinase rescued Smc5 cKO neurodevelopmental de

229 Conversely, we demonstrate that the checkpoint kinase, Rad53, inhibits DDK binding to Mcm2-7

230 toxic T lymphocyte antigen 4 (CTLA-4) immune checkpoints led to a series of clinical trials that resu

231 separate entry and exit routes and that of a checkpoint located at the gate to the T zone.

232 lated to the B7/CD28 family of T-cell immune checkpoint markers.

233 trinsic IRF5 regulates the multiple distinct checkpoints mediating T cell outcomes in vivo and IRF5-d

234 he conserved helicase PIF1 and/or DNA damage checkpoint-mediator RAD9.

235 ed for sepsis following reports of increased checkpoint molecule expression in septic patients.

236 septic patients had significantly increased checkpoint molecule expression in three or fewer studies

237 These clinical checkpoint molecule expression studies do not yet provid

238 ad significantly increased expression of any checkpoint molecule on any cell type in five or fewer st

239 tachments, it did not compromise the mitotic checkpoint, nor the phosphorylation of the Aurora B kine

240 egulators indicated ERF-1 as a potential key checkpoint of cambial activities, explaining how cambium

241 Autoimmunity can occur when a checkpoint of self-tolerance fails.

242 ls and T cells, orthogonal to PD-1 and other checkpoints of the tumor-T cell signaling axis.

243 s never suppress mTORC1 and bypass the IFRD1 checkpoint on proliferation.

244 action, RMC-4550 in combination with either checkpoint or CSF1R blockade caused additive antitumor a

245 -4):B7-1 are among the most important immune checkpoint pathways, and are key targets for immunothera

246 ularly with agents targeting the immunologic checkpoints PD-1 and CTLA-4.

247 geted at the most clinically relevant immune checkpoint, PD-1/PD-L1.

248 Despite advancements in targeting the immune checkpoints program cell death protein 1 (PD-1), program

249 e, we found that inhibiting spindle assembly checkpoint protein Msp1 partly rescued the decreased pol

250 by binding an acidic face of the kinetochore checkpoint protein, MAD1, where it coordinates NPC disas

251 erapeutics that target the T cell inhibitory checkpoint proteins CTLA-4 and PD(L)1 are efficacious ac

252 New therapeutics targeting immune checkpoint proteins have significantly advanced treatmen

253 irmed dependency on ERBB-signalling and G2/M-checkpoint proteins such as WEE1, together with the cell

254 and activated TILC2s express the inhibitory checkpoint receptor PD-1.

255 4(+) T cells, which often express the immune checkpoint receptors programmed cell death protein 1 (PD

256 mmunosuppressive cytokines and engagement of checkpoint receptors.

257 antibodies that block the immune-regulatory "checkpoint" receptors CTLA-4, PD-1, or its ligand PD-L1,

258 c) and tumor microenvironment (angiogenesis, checkpoint regulation).

259 bs cycle enzyme citrate synthase (CitA) as a checkpoint regulator controlling the G(1)->S transition

260 lation of MHC class I and down-regulation of checkpoint regulator PD-L1 on the cancer cells.

261 These CDC20(6A) cells show a normal spindle checkpoint response and rapidly destroy cyclin B once al

262 ls but also adversely affects the cell cycle checkpoint, resulting in profound chromosomal instabilit

263 ona, where it scaffolds the spindle assembly checkpoint (SAC) machinery by binding directly to MAD1.

264 ion defects and an impaired spindle assembly checkpoint (SAC), thus undergoing mitotic slippage due t

265 The CTLA4 checkpoint serves as an exemplar, whereby CTLA4 activity

266 The immune checkpoint signal axis programmed death-1/programmed dea

267 pombe Under replication stress, it initiates checkpoint signaling at the forks necessary for maintain

268 pindle assembly, but not in spindle assembly checkpoint signaling at unattached kinetochores.

269 oci (TIFs), indicating defects in DNA damage checkpoint signaling.

270 ve conformation to an inactive one, controls checkpoint strength in Caenorhabditis elegans.

271 In mouse models, immune checkpoints, such as PD-1 (programmed cell death protein

272 eased by suppression of the spindle assembly checkpoint, suggesting this effect results from chromoso

273 or of T-cell activation (VISTA) is an immune checkpoint that affects the ability of T-cells to attack

274 this context, tumour metabolism itself is a checkpoint that can limit immune-mediated tumour destruc

275 y MsrB2 is a key component of the abscission checkpoint that favors F-actin polymerization and limits

276 or of T cell activation (VISTA) is an immune checkpoint that maintains peripheral T cell quiescence a

277 To evade immune eradication, cancers exploit checkpoints that dampen T cell reactivity.

278 We discuss immunometabolic checkpoints that promote healthspan and highlight how di

279 Oncogene-targeted and immune checkpoint therapies have revolutionized the clinical ma

280 The use of immune checkpoint therapies targeting programmed death-1 (PD-1)

281 Encouraging clinical results using immune checkpoint therapies to target the PD-1 axis in a variet

282 ying factors underlying resistance to immune checkpoint therapy (ICT) is still challenging.

283 s resistance could directly influence immune checkpoint therapy failure.

284 ent with BRAF plus MEK inhibitors and immune checkpoint therapy in BRAF(V600) mutation-positive advan

285 C-B to chemotherapy and suggests that immune checkpoint therapy should be explored in this rare disea

286 -can boost the response of tumours to immune checkpoint therapy, through a mechanism that is independ

287 immunosuppression that antagonizes anti-PD-1 checkpoint therapy.

288 at control the six main peripheral tolerance checkpoints throughout the life of a T cell: quiescence,

289 t recognize cognate Ag at a defined effector checkpoint to become memory cells.

290 aturation and uncover PI3Kbeta activity as a checkpoint to ensure appropriate vessel formation.

291 support the use of CD47 as an innate immune checkpoint to mitigate IBMIR for enhanced islet engraftm

292 ls of cognate Ag recognition at the effector checkpoint to most efficiently become memory cells.

293 ls of Ag recognition throughout the effector checkpoint to optimize CD4 memory generation.

294 fection and pave the way to targeting immune checkpoints to combat recurrent ocular herpes.

295 kpoint based fitness measures to the matched checkpoint treatment naive Cancer Genome Atlas (TCGA) sa

296 for stratifying melanoma patients for immune-checkpoint treatment.

297 This checkpoint was previously modeled by the signaling of tw

298 llmark; oxidative phosphorylation and G(2)-M checkpoint were associated with moderate hypoxia, epithe

299 ould preserve rather than inhibit the CTLA-4 checkpoint while enhancing the efficacy and selectivity

300 0 and CD276 as potentially targetable immune checkpoints whose expression is independent of the EWS-W